FY2025 · ended Dec 31, 2025 · Revenue $320,000 · Filed Mar 30, 2026
Allarity Therapeutics, Inc. (ALLR) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $320,000 and a net loss of $11.2 million. Free cash flow was -$14.8 million. As of Jun 30, 2026 it held $17.0 million in cash and investments and $20.9 million in total debt.
Revenue
$320,000
Net income (TTM)
$-12.33M
+48.8% vs year-ago TTM
Operating cash flow (TTM)
$-13.71M
+18.5% vs year-ago TTM
Free cash flow
$-14.83M
+16.0% vs prior year
EPS
$-10.26
+99.7% vs prior year
Dividend per share
None
Shares outstanding
15.82M
-7.0% vs prior year
Net cash
$-3.88M
as of Jun 30, 2026
Operating margin
-3939.1%
FY 2025
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- ALLR (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Boston, MA
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1860657
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $320,000 | — | — | — | — |
| Operating income | -$12.6M | -$27.2M | -$17.1M | -$34.5M | -$26.6M |
| Net income | -$11.2M | -$24.5M | -$11.9M | -$16.1M | -$26.6M |
| Diluted EPS | — | — | -$10.26 | -$3,093.42 | — |
| Operating cash flow | -$14.8M | -$17.4M | -$12.7M | -$16.8M | -$14.9M |
| Free cash flow | -$14.8M | -$17.6M | — | -$16.8M | — |
| Total assets | $18.3M | $22.6M | $11.9M | $14.5M | $49.6M |
| Total liabilities | $8.4M | $10.8M | $14.6M | $12.7M | $30.8M |
| Stockholders' equity | $9.8M | $11.8M | -$2.8M | -$113,000 | $18.2M |
| Cash and investments | $14.7M | $19.5M | $166,000 | $2.0M | $19.9M |
| Total debt | — | — | $2.7M | $2.7M | $107,000 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Material agreement, Other events
|
Nov 2, 2026 | Oct 28, 2026 |
| 8-K |
Current report
Agreement ended
|
Oct 30, 2026 | Oct 28, 2026 |
| 8-K |
Current report
Other events
|
Oct 1, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Other events
|
Sep 29, 2026 | Sep 28, 2026 |
| 8-K |
Current report
Other events
|
Sep 16, 2026 | Sep 15, 2026 |
| 8-K |
Current report
Other events
|
Sep 14, 2026 | Sep 11, 2026 |
All 403 Allarity Therapeutics, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.